Abstract
Background: Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate. Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy, but oral 5-FU derivatives have been shown a comparable antitumor activity. Intravenous 5-FU and oral doxifluridine were compared with respect to therapeutic efficacy, drug toxicity, and quality of life.
Methods: A total of 166 patients were randomized to receive intravenous 5-FU (450 mg/m2/day) or oral doxifluridine (900 mg/m2/day) in combination with leucovorin (20 mg/m2/day) for depth of invasion, nodal status, metastasis (TNM) stage II and III patients between October 1997 and February 1999. Consecutive daily intravenous infusion for 5 days per every month for a total of 12 cycles (IV arm, n = 74) and oral doxifluridine daily for 3 weeks and 1 week rest for a total of 12 cycles (oral arm, n = 92). Drug toxicity and quality of life were observed. Quality of life was scored according to 22 daily activity items (good, ≥ 71; fair, < 70; poor, < 52).
Results: There was no difference of sex between two groups (IV arm: male/female = 45/29, oral arm: male/female = 59/33). The mean age was 52.3 vs. 59.5, respectively. There was also no difference of TNM stage distribution and type of operation between groups (P = .05). Mean numbers of chemotherapy cycles were 6.5 ± 3.7 (IV arm) vs. 7.2 ± 4.3 (oral arm), respectively. The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5%) in the oral arm, respectively (P = .937). Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II;1.1%) in the oral arm, respectively. Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively. The most common site of systemic recurrence was the liver. Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm. Diarrhea was more common in the oral arm. Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy. Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P < .05).
Conclusions: Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy. The oral regimen also can be safely given with appropriate toxicity and tolerability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allegra CJ, Grem JL. Antimetabolites in cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:432–452.
Macdonald JS. Oral fluoropyrimidines: a closer look at their toxicities. Am J Clin Oncol 1999;22:475–486.
Bajetta E, Colleoni M, Rosso R, et al. Prospective randomized trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 1993;29A:1658–1663.
Kurihara M, Shimiz H, Tsuvoi Y, et al. Evaluation of quality of life score according to protocol of anticancer chemotherapy. CRC 1992;1(4):174–181.
Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:1136–42.
Bleiberg H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin Oncol 1996;23(Suppl 3):42–50.
Pazdur R, Lassere Y, Diaz-Canton, et al. Phase I trials of uraciltegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 1996;7:728–733.
Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333–338.
Kimura K, Saito T, Taguchi T. Experimental and clinical studies on the anticancer agent doxifluridine (59-dfur). J Int Med Res 1988;16(Suppl 2):1B–37B.
Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivatives: 5-deoxy-5-fluorouridine. Eur J Cancer 1979;16:427–432.
The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301–308.
Buroker T, O’Connell M, Wieand S, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14–20.
Bajetta E, Colleoni M, Bartolomeo MD, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995;13:2613–9.
Yoshimori K, Hasegawa K. Study on efficacy and safety of 59- deoxy-5 fluorouridine (59-dFUR) with intermittent administration. Prog Antimicrob Anticancer Chemother 1987;3:493–5.
Ota K. Multicentre cooperative phase II study of 5-deoxy-5-fluorouridine in the treatment of colorectal cancer. J Int Med Res 1988;16:19B–20B.
Au JL-S, Walker JS, Rustum Y. Pharmacokinetic studies of 5-fluorouracil and 59 deoxy-5-fluorouridine in rats. J Pharmacol Exp Ther 1983;1:174–80.
Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 1998;34:1509–1513.
Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of xeloda (capecitabine) in patients with advanced colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1997;16:227.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Min, J.S., Kim, N.K., Park, J.K. et al. A Prospective Randomized Trial Comparing Intravenous 5- Fluorouracil and Oral Doxifluridine As Postoperative Adjuvant Treatment for Advanced Rectal Cancer. Ann Surg Oncol 7, 674–679 (2000). https://doi.org/10.1007/s10434-000-0674-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0674-9